Quick Facts

• May provide temporary relief for occasional constipation.
• Used for conditions requiring an easier, more comfortable bowel movement.
• Intended for short-term use only.

Agiolax Pico is used for the relief of short-term, occasional constipation in adults and adolescents over 12 years of age. It is intended to assist in promoting a bowel movement when dietary or lifestyle measures have not been sufficient. The product contains the active ingredient sodium picosulfate.

It is also used in managing certain medical conditions that require an easier passage of stool, such as hemorrhoids or anal fissures. Use is typically limited to a few days. The medicine is intended to provide temporary relief for the symptoms associated with infrequent bowel movements.

As with all laxative preparations, Agiolax Pico should be used for short durations only. If symptoms of constipation continue beyond a short treatment period, a consultation with a healthcare professional is necessary for further evaluation.

Regulatory References

1. MHRA Public Assessment Report

Agiolax Pico (Sodium Picosulfate) is officially approved for use in adults and adolescents over the age of 12 years for the short-term relief of occasional constipation. Its use is conditional; it is intended only after dietary or bulk-forming laxative measures have proven insufficient.

Populations for Whom Use is Contraindicated

The medicine must not be used by specific populations defined in regulatory labeling. This includes individuals with known hypersensitivity to the active substance or excipients, patients diagnosed with intestinal obstruction (ileus), acute inflammatory bowel diseases such as Crohn's disease or ulcerative colitis, or those experiencing severe dehydration. Use is also prohibited during acute, painful, or feverish abdominal conditions of unknown origin.

Age and Physiological Restrictions

Use is generally not recommended for children under 12 years of age. For pregnant individuals, particularly in the first trimester, and those who are breastfeeding, use is restricted and contingent upon medical advice. Elderly patients or those with renal impairment must exercise caution, as the medicine should be discontinued if they experience fluid loss.

Interactions with other medicines and products

Official regulatory documentation for Sodium Picosulfate (Agiolax Pico) details interaction patterns primarily classified as pharmacodynamic risks and pharmacokinetic interference with other substances.

Documented Pharmacodynamic and Absorption Interactions

Co-administration with Diuretics (such as thiazides or loop diuretics) and Corticosteroids is officially associated with an increased risk of hypokalaemia (low potassium levels). This electrolyte disturbance can subsequently increase the potential for Digitalis Toxicity when the medicine is combined with Cardiac Glycosides like Digoxin. Therefore, caution is required for these combinations as stated in regulatory labels.

Interactions Affecting Drug Exposure and Efficacy

The absorption of other oral medications may be reduced because Sodium Picosulfate increases the rate of gastrointestinal transit. Regulatory documents specify that certain medicines, including some oral Antibiotics (such as tetracyclines or fluoroquinolones), Oral Iron Preparations, and narrow therapeutic index drugs, should be administered with a mandated time separation to avoid impaired absorption. Furthermore, broad-spectrum Antibiotics may theoretically reduce the effectiveness of the laxative by interfering with the colonic bacteria necessary to metabolize the pro-drug into its active form. Cautions regarding magnesium accumulation in patients with renal impairment are noted for combination products that include a magnesium component.

Agiolax Pico's active ingredient, Sodium Picosulfate, functions as an inactive prodrug that requires chemical transformation to exert its effect. This conversion occurs exclusively in the large intestine, where resident bacterial sulfatase enzymes hydrolyze the molecule. This chemical transformation releases the active metabolite, BHPM. The mechanism localizes the active substance delivery to the colon. BHPM subsequently interacts with colonic epithelial cells and the enteric nervous system, modulating key physiological functions.

The BHPM metabolite engages two synergistic mechanistic domains. First, it stimulates enteric neurons, leading to enhanced propulsive motility that accelerates the movement of intestinal contents. Second, it modulates fluid transport by inhibiting the reabsorption of water and sodium while promoting the active secretion of chloride ions and water into the lumen. These combined physiological actions facilitate the hydration of the fecal mass and increase its propulsion through the large bowel.

Full mechanistic engagement is dependent on the time necessary for the prodrug to transit to the colon and undergo bacterial bioactivation. This obligate, two-step molecular process dictates the delayed onset of action, typically 6–12 hours, before full pharmacological engagement occurs.

Agiolax Pico, a medicine containing Sodium Picosulfate, is administered according to an established regimen for the short-term relief of occasional constipation. Standard guidelines describe the route, dose, and duration to ensure predictable use.

---

Official Administration Guidelines

Parameter	Specification
Route of administration	Oral (by mouth).
Dosing schedule (Adults/Adolescents)	The usual starting dose is 5 mg (e.g., one 5 mL spoonful of oral solution), and the dose may be adjusted up to the maximum recommended daily dose of 10 mg.
Frequency and Timing	The medicine is taken Once Daily, typically administered at night (at bedtime). This timing aligns with the drug's 6 to 12 hour onset of action to produce an evacuation the following morning.
Preparation requirements	The liquid formulation can be taken directly or may be diluted with water or a soft drink. Tablets should be swallowed whole with adequate fluid.
Age-group rules	Use in children under 10 or 12 years is generally not recommended unless under medical advice, with specific lower maximum doses where authorized.

---

Use-Context Constraints

Treatment is intended for short-term relief only. Guidelines indicate that the medicine should not be taken on a continuous daily basis for more than five days without further clinical investigation. During the entire course of use, the maintenance of adequate fluid intake is essential. The dose may be individually titrated up to the daily maximum to restore regular bowel function, after which the dosage should be reduced and can be stopped.

Agiolax Pico: Recent Clinical Evidence

Evidence for Use in Short-Term Use in Constipation

Sodium Picosulfate, the active ingredient in Agiolax Pico, research examined short-term use in patients with functional constipation. The research base includes randomized controlled trials (RCTs), which are commonly used to measure symptom change, alongside systematic reviews that combine findings from multiple studies. These trials primarily focused on adult populations with conditions characterized by fluctuating or episodic manifestations.

Research examined objective measures such as the frequency of bowel movements over defined time intervals, and also monitored the measurement of symptoms in the observed populations. Trials assessed outcomes related to systemic or functional imbalance, specifically looking at changes in stool consistency and the amount of straining reported by patients. Findings describe patterns observed in the studies that contribute to the broader evidence landscape.

Research on Specific Clinical Situations

Studies have explored the use of this medicine in patient groups, such as individuals with anal fissures or hemorrhoids. In these cases, research was applied in studies examining patient-reported experiences related to stool passage characteristics. This evidence contributes to understanding symptom patterns in conditions marked by functional limitations where physiological strain or stress is a factor. The research describes the symptoms and outcomes that were monitored in these specific patient groups over the study period.

Long-Term Evidence and Follow-up Durations

The available clinical data largely stems from trials relevant in trials assessing short-term or episodic symptom patterns. The core high-quality RCTs were conducted during periods of increased symptom activity and typically monitored patient responses over defined time intervals of up to four weeks. These short durations reflect the typical application studied in the research, however, long-term effects are not fully established by prospective, long-duration trials. There is limited information for long-term outcomes, as research exploring extended use is typically observational rather than controlled.

Evidence in Different Patient Groups

The body of evidence is mainly derived from studies that focused on adults with functional constipation. Research was evaluated in this core population to understand the short-term response. Data for certain groups remain insufficient; for example, specific, dedicated studies focusing only on older adults or patients with complex, comorbid conditions are still emerging. While the medicine is authorized for use in adolescents, data for certain groups remain insufficient and findings often describe group patterns established in adult populations.

The Research Landscape: Consistency and Uncertainty

The overall evidence quality varies across studies, and systematic reviews frequently assign a moderate evidence level to Sodium Picosulfate. Research provides insight into short-term changes. However, certainty remains low for some complex or long-term questions. Evidence is limited in situations outside the specific parameters of the clinical trials, and comparative evidence is lacking. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly to the patterns observed in the studies.

Key Studies & References

1. Over-the-counter stimulant laxatives: benefit-risk review – Public assessment report (MHRA)
2. Clinical Guideline: Chronic constipation

Common questions about Agiolax Pico (FAQ)

---

Q: Can Agiolax Pico be used for chronic constipation?

A: Official documentation describes this product's authorized use strictly for the short-term relief of occasional constipation. Regulatory standards specify that the medicine should not be taken on a continuous daily basis for more than five days without further medical investigation. This guidance establishes the scope of its authorization as short-term.

---

Q: What is the difference between Agiolax Pico and a stool softener?

A: Agiolax Pico's active ingredient, Sodium Picosulfate, is classified as a Stimulant Laxative. It is described as working by stimulating the natural muscle contractions of the colon to encourage movement. Stool softeners are a separate class of medicine that primarily works by increasing the water content in the stool to make it softer and easier to pass.

---

Q: Is the onset time of Agiolax Pico affected by food?

A: Official instructions specify that the medicine is administered once daily, often at night, and can be taken with water or a soft drink. The full effect is typically reported to occur 6–12 hours later, but official documents do not explicitly detail whether consumption of food affects this expected onset time.

---

Q: What does official guidance say about using Agiolax Pico during pregnancy or breastfeeding?

A: Regulatory guidance states that use during pregnancy or lactation is restricted, and regulatory documents state its use is contingent upon medical advice. For pregnant individuals, use, particularly in the first trimester, is generally contingent upon a healthcare professional's assessment.

---

Q: Does Agiolax Pico contain sugar or gluten?

A: Official product labeling, which lists the excipients (inactive ingredients), details all components of the specific formulation. The presence of substances like sugar or gluten varies by product type (e.g., granules vs. oral solution). Patients typically confirm this information by reviewing the excipients list in the patient information leaflet for their specific product.

---

Q: Is Agiolax Pico the same drug as other products containing sodium picosulfate?

A: Agiolax Pico contains Sodium Picosulfate as its single active ingredient. Other products containing this same active substance share the same key mechanism of action. However, the specific product name refers to that exact formulation, strength, and combination of other ingredients (excipients) as defined by its regulatory approval.

---

Q: Does Agiolax Pico affect the absorption of vitamins or supplements?

A: Official documents note that the increased rate of gastrointestinal transit caused by this medicine may reduce the absorption of other oral medications. While vitamins and supplements are not explicitly named, the regulatory text indicates that the general principle of altered absorption applies to orally administered substances.

---

Q: Are there any specific lifestyle changes mentioned alongside Agiolax Pico use in official documents?

A: Yes, regulatory documents emphasize that the maintenance of adequate fluid intake is officially essential during the entire course of treatment. This requirement is emphasized, particularly for certain groups such as elderly patients.

---

Q: Do you get withdrawal symptoms after stopping Agiolax Pico?

A: Official documentation does not typically use the term 'withdrawal symptoms.' However, regulatory warnings note that prolonged or excessive use may potentially result in physical dependence, which is a warning related to the body potentially becoming dependent on the medicine's effect.

---

Q: Does Agiolax Pico cause dependence if used for a short time?

A: Official labeling primarily states that the potential risk of dependence is associated with prolonged or excessive use of the medicine. Because the product is authorized and intended for short-term use, the focus of official documents is on the risk associated with prolonged or excessive exposure.

---

Q: What is the purpose of the 'Pico' part of the name?

A: The name 'Pico' refers to the chemical name of the active substance, Sodium Picosulfate, which is a salt derived from Picosulfuric acid. This naming convention is common in pharmaceuticals and helps to identify the core chemical family of the product.

---

Q: Does Agiolax Pico contain natural ingredients, besides the active substance?

A: The active ingredient, Sodium Picosulfate, is a synthetic compound. The other components of the medicine are known as excipients, which are used to create the final form, such as liquid or granules. The official documentation lists all components, which may include both synthetic and naturally derived substances.

---

Q: Do the effects of Agiolax Pico last into the next day?

A: The medicine is typically taken at night because its delayed onset of action, which is usually 6 to 12 hours, is intended to produce a bowel movement the following morning. The intended pharmacological effect is associated with the resulting bowel evacuation.

---

Q: What is the general patient expectation for time until relief with Agiolax Pico?

A: The mechanism of action dictates a delayed onset for the medicine to work. The full effect typically occurs between 6 to 12 hours after the dose is taken. This time frame represents the period in which a bowel movement is typically expected.

---

Q: How do you store Agiolax Pico after the bottle or box has been opened?

A: Official instructions define specific storage conditions, such as temperature, protection from light and moisture, and keeping the medicine out of the sight and reach of children. For liquid solutions, official documents often define a shelf-life (e.g., 4 weeks) for the product after the bottle has been opened for the first time.

---

Q: What are the signs that Agiolax Pico is working?

A: As a laxative, the medicine is indicated for managing occasional constipation by promoting a bowel evacuation. The primary sign that the medicine is working is the occurrence of a bowel movement within the expected time frame of 6 to 12 hours after taking the dose.

---

Q: Does Agiolax Pico make you feel bloated?

A: Official safety documents classify common reactions in the gut as abdominal discomfort or abdominal cramps. These terms are used to describe sensations in the abdomen that are reported in regulatory safety documents.

---

Q: Is it normal to feel a mild sensation in the gut after taking Agiolax Pico?

A: The medicine works by stimulating the natural muscle movement (motility) in the colon. Common side effects listed in regulatory documents include abdominal discomfort and abdominal cramps. These are sensations related to the drug's mechanism of action as it promotes bowel function.

---

Q: Can Agiolax Pico be taken with milk or juice?

A: Regulatory documents state that the liquid formulation can be taken directly or may be diluted with water or a soft drink. Official instructions do not typically specify milk or juice, though some high-dose regulatory information notes that clear liquids may include juice without pulp.

---

Q: Does Agiolax Pico have a taste?

A: Official product documentation describes the formulation and its excipients. Many products are formulated with flavorings designed to make the product palatable. The actual taste will depend on the specific formulation and excipients used in your product.

Official Storage and Disposal Instructions

Regulatory requirements govern how Agiolax Pico, or similar sodium picosulfate products, must be stored and disposed of to ensure stability and public safety.

Storage Scope	Requirement
Temperature	Store below 30 C (room temperature), away from heat.
Protection	Keep in the original container or carton to protect it from light and moisture.
Child Safety	Keep this medicine out of the sight and reach of children.
Post-Opening	If the product is reconstituted (e.g., from a sachet), it must be used immediately and any remainder discarded.

Disposal must follow specific guidelines: Do not throw away any medicines via wastewater or household waste as this can harm the environment. Instead, return expired or unused medicine to a pharmacist or local collection scheme for proper disposal.